ALZAI-CTR

AI-Powered Patient Prioritization to Reduce Screen Failures & Accelerate Recruitment

THE PROBLEM

Alzheimer's trials are derailed before they start by **~95% screen failure rates**

- Early-stage subjects are nearly impossible to identify
- Diagnostics are **costly and invasive**
- No systematic **data-driven pre-screening**

Massive clinical trial burden:

- $8,000–$12,000 cost per screened subject
- Average 2.5 years recruitment timelines
- Tens of thousands of candidate subjects required

THE ALZAI-CTR SOLUTION

ALZAI-CTR plugs into your existing pre-screening workflow to prioritize subjects — cutting screen failure rates in half with no new testing required.

ALZAI-CTR can:

- Flag subjects at **high risk for Alzheimer's Disease**
- Refine large cohorts to smaller **higher-probability cohorts**
- **Reduce waste** in screening time and cost

Key advantages:

- Non-invasive. No new testing required
- Integrates seamlessly, scales easily
- Reduce screen failure, Accelerate recruitment

ALZAI-CTR: ENRICHED PRE-SCREENING

Adding ALZAI analysis to pre-screening delivers an automated prioritization of subjects by their risk of being diagnosed with AD stratified by time horizon, creating a smaller enriched pool of subjects for screening



75% less screening to achieve the same result

ALZAI enriched pre-screening = greater precision, faster recruitment, less risk

ALZAI's new patented Pre-Screening AI solution proven on over 1.6M patients

info@alzaihealth.com
+1.416.727.6244
https://www.alzaihealth.com